1. Home
  2. QTTB vs EVMN Comparison

QTTB vs EVMN Comparison

Compare QTTB & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

N/A

Current Price

$8.51

Market Cap

265.2M

Sector

Health Care

ML Signal

N/A

Logo Evommune Inc.

EVMN

Evommune Inc.

N/A

Current Price

$7.26

Market Cap

284.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QTTB
EVMN
Founded
2015
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
265.2M
284.5M
IPO Year
2018
2025

Fundamental Metrics

Financial Performance
Metric
QTTB
EVMN
Price
$8.51
$7.26
Analyst Decision
Strong Buy
Buy
Analyst Count
7
12
Target Price
★ $39.67
$21.89
AVG Volume (30 Days)
322.9K
★ 921.5K
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 136.78
75.23
EPS
★ N/A
N/A
Revenue
★ $53,737,000.00
$13,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$40.00
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 85.71
52 Week Low
$1.93
$4.94
52 Week High
$23.57
$33.20

Technical Indicators

Market Signals
Indicator
QTTB
EVMN
Relative Strength Index (RSI) 41.77 50.77
Support Level $8.23 $4.94
Resistance Level $9.41 $7.21
Average True Range (ATR) 0.54 0.70
MACD -0.01 0.11
Stochastic Oscillator 20.24 40.84

Price Performance

Historical Comparison
QTTB
EVMN

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

About EVMN Evommune Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Share on Social Networks: